TY - JOUR
T1 - Therapeutic Potential of Intravenous Phage as Standalone Therapy for Recurrent Drug-Resistant Urinary Tract Infections
AU - Le, Tram
AU - Nang, Sue C.
AU - Zhao, Jinxin
AU - Yu, Heidi H.
AU - Li, Jian
AU - Gill, Jason J.
AU - Liu, Mei
AU - Aslam, Saima
N1 - Funding Information:
The work conducted at the Center for Phage Technology was supported by funding from Texas A&M University, Texas AgriLife Research. The work performed at the University of California, San Diego (UCSD), was supported by a grant from the UC San Diego Chancellor’s Innovation Fund and the Monash-UCSD Seed Fund. The work performed at Monash University was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R21 AI156766) and the Monash-UCSD Seed Fund. J.L. is a National Health and Medical Research Council (NHMRC) Principal Research Fellow (APP1157909).
Funding Information:
J.J.G. is a member of the Scientific Advisory Board for Deerland Enzymes, Inc., and Janssen. S.A. is a consultant for BioMx and Phico, a member of Medical Advisory Board for Pherecydes Pharma, and received research funding from the Contrafect Corporation, Armata Pharmaceuticals, Cystic Fibrosis Foundation, and National Institutes of Health (U19 AI157981, UL1 TR001442). No other author has a conflict of interest to declare.
Funding Information:
We thank Cara Fiore and Nikunj Sharma at the Food and Drug Administration. The work conducted at the Center for Phage Technology was supported by funding from Texas A&M University, Texas AgriLife Research. The work performed at the University of California, San Diego (UCSD), was supported by a grant from the UC San Diego Chancellor’s Innovation Fund and the Monash-UCSD Seed Fund. The work performed at Monash University was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R21 AI156766) and the Monash-UCSD Seed Fund. J.L. is a National Health and Medical Research Council (NHMRC) Principal Research Fellow (APP1157909). J.J.G. is a member of the Scientific Advisory Board for Deerland Enzymes, Inc., and Janssen. S.A. is a consultant for BioMx and Phico, a member of Medical Advisory Board for Pherecydes Pharma, and received research funding from the Contrafect Corporation, Armata Pharmaceuticals, Cystic Fibrosis Foundation, and National Institutes of Health (U19 AI157981, UL1 TR001442). No other author has a conflict of interest to declare.
Funding Information:
Copyright © 2023 American Society for Microbiology. All Rights Reserved. Address correspondence to Saima Aslam, [email protected], @DocSaimaAslam, or Mei Liu, [email protected]. The authors declare a conflict of interest. T.L. - none, S.C.N. - none, J.Z. - none, J.L. - none, H.H.Y. - none, J.J.G. - Scientific Advisory Board for Deerland Enzymes Inc., and Janssen. M.L. - none, S.A. - Consultant for BioMx and Phico, Medical Advisory Board Phereycedes, Research funding from Contrafect Corporation, Armata Pharmaceuticals, Cystic Fibrosis Foundation, and National Institutes of Health (U19 AI157981, UL1 TR001442). Received 9 January 2023 Returned for modification 29 January 2023 Accepted 21 February 2023 Published 28 March 2023
Publisher Copyright:
Copyright © 2023 American Society for Microbiology. All Rights Reserved.
PY - 2023/4
Y1 - 2023/4
N2 - Recurrent urinary tract infections (rUTI) are common in kidney transplant recipients (KTR) and are associated with multidrug resistance and increased morbidity/ mortality. Novel antibiotic alternatives to reduce UTI recurrence are critically needed. We describe a case of rUTI due to extended spectrum beta lactamase (ESBL) Klebsiella pneumoniae in a KTR that was treated successfully with 4 weeks of adjunctive intravenous bacteriophage therapy alone, without concomitant antibiotics, and with no recurrence in a year of follow-up.
AB - Recurrent urinary tract infections (rUTI) are common in kidney transplant recipients (KTR) and are associated with multidrug resistance and increased morbidity/ mortality. Novel antibiotic alternatives to reduce UTI recurrence are critically needed. We describe a case of rUTI due to extended spectrum beta lactamase (ESBL) Klebsiella pneumoniae in a KTR that was treated successfully with 4 weeks of adjunctive intravenous bacteriophage therapy alone, without concomitant antibiotics, and with no recurrence in a year of follow-up.
KW - bacteriophage
KW - ESBL
KW - kidney transplant
KW - phage
KW - rUTI
UR - http://www.scopus.com/inward/record.url?scp=85152975152&partnerID=8YFLogxK
U2 - 10.1128/aac.00037-23
DO - 10.1128/aac.00037-23
M3 - Article
C2 - 36975787
AN - SCOPUS:85152975152
SN - 0066-4804
VL - 67
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 4
M1 - e00037-23
ER -
